Abstract

In the view of constantly increasing number of reports about participation of advanced oxidation protein products (AOPPs) in pathogenesis of many diseases as well as in the pathomechanism of their biochemical disturbances and clinical complications, the possibility of treatment of these diseases by reducing of AOPPs concentration and prevention or inhibition of their formation poses the object of intensive investigations. The first investigated agents, with proven efficacy in prevention of AOPPs formation, was N-acetylcysteine. In relationship with the fact, that the intensified formation of AOPPs is closely connected with intensity of oxidative stress (OS), so the possibility of use of agents and/or drugs with well-known antioxidative proprieties, also natural origin, was examined. It is very important in aspects of its self-treatment by patients. The next step was the estimation of possibility of utilization of pleiotropic properties of drugs routinely applied in the treatment of civilization diseases, especially hypertension and diabetes, often with kidneys insufficiency. On the basis of known mechanism of the unfavorable acting of AOPPs (induction of intracellular signal transduction, and secondary intensyfication of OS), on the way of its connection with the RAGE receptor [similarly as advanced glycation end products (AGEs)], indicated on the possibility of new therapeutic strategies, through the blocking of RAGE-AGEs interactions or using the soluble form of this receptor. Discussed in this paper results of investigations shows the possibility to introduction in the near future, the innovative therapeutic strategies, directed just on the AOPPs, permitting on the limitation of their formation and accumulation in tissues and organs, especially in kidneys. This will permit for the break of mechanism of vicious circle of interaction OS and oxidatively modified macromolecules and attenuating of biochemical and clinical disturbances in the diseases connected with AOPPs participating.

References

• 1. Anraku M., Kitamura K., Shintomo R., Takeuchi K., Ikeda H., NaganoJ., Ko T., Mera K., Tomita K., Otagiri M.: Effect of intravenousiron administration frequency on AOPP and inflammatory biomarkersin chronic hemodialysis patients: a pilot study. Clin. Biochem.,2008; 41: 1168-1174
  Google Scholar
• 2. Ardestani A., Yazdanparast R., Jamshidi S.: Therapeutic effects ofTeucrium polium extract on oxidative stress in pancreas of streptozotocin-induceddiabetic rats. J. Med. Food, 2008; 11: 525-532
  Google Scholar
• 3. Atukeren P., Aydin S., Uslu E., Gumustas M.K., Cakatay U.: Redoxhomeostasis of albumin in relation to alpha-lipoic acid and dihydrolipoicacid. Oxid. Med. Cell. Longev., 2010; 3: 206-213
  Google Scholar
• 4. Baba S.P., Hellmann J., Srivastava S., Bhatnagar A.: Aldose reductase(AKR1B3) regulates the accumulation of advanced glycosylationend products (AGEs) and the expression of AGE receptor (RAGE).Chem. Biol. Interact., 2011; 191: 357-363
  Google Scholar
• 5. Baskol G., Demir H., Baskol M., Kilic E., Ates F., Karakukcu C.,Ustdal M.: Investigation of protein oxidation and lipid peroxidationin patients with rheumatoid arthritis. Cell Biochem. Funct.,2006; 24: 307-311
  Google Scholar
• 6. Bochi G.V., Torbitz V.D., Cargnin L.P., Sangoi M.B., Santos R.C.,Gomes P., Moresco R.N.: Fructose-1,6-bisphosphate and N-acetylcysteineattenuate the formation of advanced oxidation proteinproducts, a new class of inflammatory mediators, in vitro. Inflammation,2012; 35: 1786-1792
  Google Scholar
• 7. Cao W., Xu J., Zhou Z.M., Wang G.B., Hou F.F., Nie J.: Advancedoxidation protein products activate intrarenal renin-angiotensinsystem via a CD36-mediated, redox-dependent pathway. Antioxid.Redox Signal., 2013; 18: 19-35
  Google Scholar
• 8. Celec P., Jurkovičová I., Buchta R., Bartík I., Gardlík R., Pálffy R.,Mucska I., Hodosy J.: Antioxidant vitamins prevent oxidative andcarbonyl stress in an animal model of obstructive sleep apnea. SleepBreath., 2013, 17: 867-871
  Google Scholar
• 9. Chakraborty A., Chowdhury S., Bhattacharya M.: Effect of metforminon oxidative stress, nitrosative stress and inflammatory biomarkersin type 2 diabetes patients. Diabetes Res. Clin. Pract., 2011;93: 56-62
  Google Scholar
• 10. Chen S., Liu L., Sun X., Liu Y., Song T.: Captopril restores endothelium-dependentrelaxation induced by advanced oxidation proteinproducts in rat aorta. J. Cardiovasc. Pharmacol., 2005; 46: 803-809
  Google Scholar
• 11. Chen S.X., Song T., Zhou S.H., Liu Y.H., Wu S.J., Liu L.Y.: Protectiveeffects of ACE inhibitors on vascular endothelial dysfunctioninduced by exogenous advanced oxidation protein products in rats.Eur. J. Pharmacol., 2008; 584: 368-375
  Google Scholar
• 12. Cumaoglu A., Ozansoy G., Irat A.M., Arıcıoglu A., Karasu C., AriN.: Effect of long term, non cholesterol lowering dose of fluvastatintreatment on oxidative stress in brain and peripheral tissuesof streptozotocin-diabetic rats. Eur. J. Pharmacol., 2011; 654: 80-85
  Google Scholar
• 13. Cumaoglu A., Stefek M., Bauer V., Ari N., Aricioglu A., Karasu C.:Glycoxidative and nitrosative stress in kidney of experimental diabeticrats: effects of the prydoindole antioxidant stobadine. Neuro.Endocrinol. Lett., 2010; 31: 313-318
  Google Scholar
• 14. Demirbilek M.E., Kilic N., Komurcu H.F., Akin K.O.: Advancedoxidation protein products in aged with dementia. Am. J. Immunol.,2007; 3: 52-55
  Google Scholar
• 15. Djordjevic B., Baralic I., Kotur-Stevuljevic J., Stefanovic A., IvanisevicJ., Radivojevic N., Andjelkovic M., Dikic N.: Effect of astaxanthinsupplementation on muscle damage and oxidative stressmarkers in elite young soccer players. J. Sports Med. Phys. Fitness,2012; 52: 382-392
  Google Scholar
• 16. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M.: N-acetylcysteinefor antioxidant therapy: pharmacology and clinical utility.Expert Opin. Biol. Ther., 2008; 8: 1955-1962
  Google Scholar
• 17. El-Khawaga O.Y., Abou-Seif M.A.: Biochemical studies on antioxidantand oxidant activities of some plant extracts. Eur. Rev. Med.Pharmacol. Sci., 2010; 14: 731-738
  Google Scholar
• 18. Esteghmati A., Eskandari D., Mirmiranpour H., Noshad S., MousavizadehM., Hedayati M., Nakhjavani M.: Effects of metforminon markers of oxidative stress and antioxidant reserve in patientswith newly diagnosed type 2 diabetes: a randomized clinical trial.Clin. Nutr., 2013; 32: 179-185
  Google Scholar
• 19. Fabian E., Gerstorfer I., Thaler H.W., Stundner H., Biswas P.,Elmadfa I.: Nutritional supplementation affects postoperative oxidativestress and duration of hospitalization in patients with hipfracture. Wien. Klin. Wochenschr., 2011; 123: 88-93
  Google Scholar
• 20. Fassett R.G., Coombes J.S.: Astaxanthin in cardiovascular healthand disease. Molecules, 2012; 17: 2030-2048
  Google Scholar
• 21. Gallardo J.M., Prado-Uribe M.C., Amato D., Paniagua R.: Inflammationand oxidative stress markers by pentoxifylline treatment inrats with chronic renal failure and high sodium intake. Arch. Med.Res., 2007; 38: 34-38
  Google Scholar
• 22. Gąsior M., Czekaj A.D., Przybylska K., Janecka A.M., SiedleckiŁ.: Plejotropowe działanie statyn. Choroby Serca i Naczyń, 2008;5: 141-145
  Google Scholar
• 23. Gleisner A., Martinez L., Pino R., Rojas I.G., Martinez A., AsenjoS., Rudolph M.I.: Oxidative stress markers in plasma and urine ofprepubertal patients with type 1 diabetes mellitus. J. Pediatr. Endocrinol.Metab., 2006; 19: 995-1000
  Google Scholar
• 24. Grossin N., Boulanger E., Wautier M.P., Wautier J.L.: The differentisoforms of the receptor for advanced glycation end productsare modulated by pharmacological agents. Clin. Hemorheol. Microcirc.,2010; 45: 143-153
  Google Scholar
• 25. Guo Z.J., Niu H.X., Hou F.F., Zhang L., Fu N., Nagai R., Lu X., ChenB.H., Shan Y.X., Tian J.W., Nagaraj R.H., Xie D., Zhang X.: Advancedoxidation protein products activate vascular endothelial cells viaa RAGE-mediated signaling pathway. Antioxid. Redox Signal., 2008;10: 1699-1712
  Google Scholar
• 26. Hegab Z., Gibbons S., Neyses L., Mamas M.A.: Role of advancedglycation end products in cardiovascular disease. World J. Cardiol.,2012; 4: 90-102
  Google Scholar
• 27. Hodkova M., Dusilova-Sulkova S., Skalicka A., Kalousova M., ZimaT., Bartunkova J.: Influence of parenteral iron therapy and oral vitaminE supplementation on neutrophil respiratory burst in chronichemodialysis patients. Ren. Fail., 2005; 27: 135-141
  Google Scholar
• 28. Jasińska M., Owczarek J., Orszulak-Michalak D.: Statins: a newinsight into their mechanisms of action and consequent pleiotropiceffects. Pharmacol. Rep., 2007; 59: 483-499
  Google Scholar
• 29. Kalousová M., Skrha J., Zima T.: Advanced glycation end-productsand advanced oxidation protein products in patients with diabetesmellitus. Physiol. Res., 2002; 51: 597-604
  Google Scholar
• 30. Kalousová M., Zák A., Soukupová J., Stipek S., Malbohan I.M.,Zima T.: Advanced glycation and oxidation products in patients withatherosclerosis. Cas. Lek. Cesk., 2005: 144: 385-389
  Google Scholar
• 31. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., Ohno M.: Increasedlevel of advanced oxidation protein products in patientswith coronary artery disease. Atherosclerosis, 2002; 162: 221-225
  Google Scholar
• 32. Kiliś-Pstrusińska K.: Karnozyna i karnozynaza a choroby nerek.Postępy Hig. Med. Dośw., 2012; 66: 215-221
  Google Scholar
• 33. Koc E., Reis K.A., Ebinc F.A., Pasaoglu H., Demirtas C., OmerogluS., Derici U.B., Guz G., Erten Y., Bali M., Arinsoy T., Sindel S.: Protectiveeffect of beta-glucan on contrast induced-nephropathy anda comparison of beta-glucan with nebivolol and N-acetylcysteinein rats. Clin. Exp. Nephrol., 2011; 15: 658-665
  Google Scholar
• 34. Kołodziej T., Szybejko-Machaj G., Kubicka V., Białynicki-BirulaR.: Pentoksyfilina w leczeniu zaostrzeń atopowego zapalenia skóryu dzieci. Dermatologia Kliniczna, 2003; 5: 17-19
  Google Scholar
• 35. Lazárová M., Stejskal D., Lacnák B., Václavík J., Adamovská S.,Ochmanová R., Hanák V., Skácelová M.: The antioxidant acetylcysteinereduces oxidative stress by decreasing level of AOPPs. Biomed. Pap.Med. Fac. Univ. Palacky Olomouc Czech Repub., 2004; 148: 131-133
  Google Scholar
• 36. Lee S.H., Nam B.Y., Kang E.W., Han S.H., Li J.J., Kim do H., Kim S.H.,Kwak S.J., Park J.T., Chang T.I., Yoo T.H., Han D.S., Kang S.W.: Effectsof an oral adsorbent on oxidative stress and fibronectin expressionin experimental diabetic nephropathy. Nephrol. Dial. Transplant.,2010; 25: 2134-2141
  Google Scholar
• 37. Licastro F., Dogliotti G., Goi G., Malavazos A.E., Chiappelli M.,Corsi M.M.: Oxidated low-density lipoproteins (oxLDL) and peroxidesin plasma of Down syndrome patients. Arch. Gerontol. Geriatr.,2007; 44 (Suppl. 1): 225-232
  Google Scholar
• 38. Liu H., Han T., Tian J., Zhu Z.Y., Liu Y., Li Y., Xiao S.X., Li Y., FengY.Y.: Monitoring oxidative stress in acute-on-chronic liver failureby advanced oxidation protein products. Hepatol. Res., 2012; 42:171-180
  Google Scholar
• 39. Madian A.G., Myracle A.D., Diaz-Maldonado N., Rochelle N.S.,Janle E.M., Regnier F.E.: Determining the effects of antioxidants onoxidative stress induced carbonylation of proteins. Anal. Chem.,2011; 83: 9328-9336
  Google Scholar
• 40. Mancuso M., Orsucci D., Logerfo A., Rocchi A., Petrozzi L., NestiC., Galetta F., Santoro G., Murri L., Siciliano G.: Oxidative stress biomarkersin mitochondrial myopathies, basally and after cysteinedonor supplementation. J. Neurol., 2010; 257: 774-781
  Google Scholar
• 41. Meaney E., Vela A., Samaniego V., Meaney A., Asbun J., ZempoaltecaJ.C., Elisa Z.N., Emma M.N., Guzman M., Hicks J., Ceballos G.:Metformin, arterial function, intima-media thickness and nitroxidationin metabolic syndrome: the mefisto study. Clin. Exp. Pharmacol.Physiol., 2008; 35: 895-903
  Google Scholar
• 42. Morsy M.D., Mostafa O.A., Hassan W.N.: A potential protectiveeffect of α-tocopherol on vascular complication in spinal cord reperfusioninjury in rats. J. Biomed. Sci., 2010; 17: 55
  Google Scholar
• 43. Nascimento M.M., Suliman M.E., Silva M., Chinaglia T., MarchioroJ., Hayashi S.Y., Riella M.C., Lindholm B., Anderstam B.: Effectof oral N-acetylcysteine treatment on plasma inflammatory andoxidative stress markers in peritoneal dialysis patients: a placebocontrolledstudy. Perit. Dial. Int., 2010; 30: 336-342
  Google Scholar
• 44. Nemzer B.V., Rodriguez L.C., Hammond L., Disilvestro R., HunterJ.M., Pietrzkowski Z.: Acute reduction of serum 8-iso-PGF2-alphaand advanced oxidation protein products in vivo by a polyphenolrichbeverage; a pilot clinical study with phytochemical and in vitroantioxidant characterization. Nutr. J., 2011; 10: 67
  Google Scholar
• 45. Nie J., Hou F.F.: Role of reactive oxygen species in the renal fibrosis.Chin. Med. J., 2012; 125: 2598-2602
  Google Scholar
• 46. Noyan T., Güler A., Sekeroglu M.R., Kamaci M.: Serum advancedoxidation protein products, myeloperoxidase and ascorbic acid inpre-eclampsia and eclampsia. Aust. N.Z. J. Obstet. Gynaecol., 2006;46: 486-491
  Google Scholar
• 47. Ozdem S., Nacitarhan C., Gulay M.S., Hatipoglu F.S., Ozdem S.S.:The effect of ascorbic acid supplementation on endosulfan toxicityin rabbits. Toxicol. Ind. Health, 2011; 27: 437-446
  Google Scholar
• 48. Páez P.L., Becerra M.C., Albesa I.: Comparison of macromolecularoxidation by reactive oxygen species in three bacterial generaexposed to different antibiotics. Cell Biochem. Biophys., 2011; 61:467-472
  Google Scholar
• 49. Pietkiewicz J., Seweryn E., Bartyś A., Gamian A.: Receptory koń-cowych produktów zaawansowanej glikacji – znaczenie fizjologicznei kliniczne. Postępy Hig. Med. Dośw., 2008; 62: 511-523
  Google Scholar
• 50. Piwowar A.: Zaawansowane produkty utleniania białek. CzęśćI. Mechanizm powstawania, struktura i właściwości. Pol. Merkur.Lekarski, 2010; 28: 166-169
  Google Scholar
• 51. Piwowar A.: Aspekty biochemiczne i kliniczne zaawansowanychproduktów utleniania białek w chorobach nerek i zaburzeniach metabolicznych.Postępy Hig. Med. Dośw., 2014; 68: 179-190
  Google Scholar
• 52. Piwowar A.: Zaawansowane produkty utleniania białek jakopotencjalny czynnik diagnostyczny i prognostyczny w chorobacho wskazywanym udziale stresu oksydacyjnego. Postępy Hig. Med.Dośw., 2014; 68: 446-458
  Google Scholar
• 53. Piwowar A., Knapik-Kordecka M., Warwas M.: AOPP and its relationswith selected markers of oxidative/antioxidative system intype 2 diabetes mellitus. Diabetes Res. Clin. Pract., 2007; 77: 188-192
  Google Scholar
• 54. Ramasamy R., Yan S.F., Schmidt A.M.: Receptor for AGE (RAGE):signaling mechanisms in the pathogenesis of diabetes and its complications.Ann. N.Y. Acad. Sci., 2011; 1243: 88-102
  Google Scholar
• 55. Rybka J., Kędziora-Kornatowska K., Kupczyk D., Kozakiewicz M.,Czuczejko J., Szewczyk-Golec K., Szypuła J., Kędziora J., Błaszczak R.:Ocena parametrów stresu oksydacyjnego u chorych w wieku podeszłymleczonych z powodu pierwotnego nadciśnienia tętniczegow porównaniu z chorymi leczonymi z powodu cukrzycy typu 2 orazosobami zdrowymi. Przegląd Kardiodiabetologiczny, 2011; 6: 234-242
  Google Scholar
• 56. Said U.Z., Saada H.N., Abd-Alla M.S., Elsayed M.E., Amin A.M.:Hesperidin attenuates brain biochemical changes of irradiated rats.Int. J. Radiat. Biol., 2012; 88: 613-618
  Google Scholar
• 57. Sefi M., Fetoui H., Makni M., Zeghal N.: Mitigating effects of antioxidantproperties of Artemisia campestris leaf extract on hyperlipidemia,advanced glycation end products and oxidative stress in alloxan-induceddiabetic rats. Food Chem. Toxicol., 2010; 48: 1986-1993
  Google Scholar
• 58. Sefi M., Fetoui H., Soudani N., Chtourou Y., Makni M., Zeghal N.:Artemisia campestris leaf extract alleviates early diabetic nephropathyin rats by inhibiting protein oxidation and nitric oxide end products. Pathol. Res. Pract., 2012; 208: 157-162
  Google Scholar
• 59. Selmeci L., Seres L., Antal M., Lukács J., Regöly-Mérei A., AcsádyG.: Advanced oxidation protein products (AOPP) for monitoringoxidative stress in critically ill patients: a simple, fast and inexpensiveautomated technique. Clin. Chem. Lab. Med., 2005; 43: 294-297
  Google Scholar
• 60. Servettaz A., Guilpain P., Goulvestre C., Chéreau C., Hercend C.,Nicco C., Guillevin L., Weill B., Mouthon L., Batteux F.: Radical oxygenspecies production induced by advanced oxidation protein productspredicts clinical evolution and response to treatment in systemicsclerosis. Ann. Rheum. Dis., 2007; 66: 1202-1209
  Google Scholar
• 61. Skvarilová M., Bulava A., Stejskal D., Adamovská S., Bartek J.:Increase level of advanced oxidation products (AOPP) as a marker ofoxidative stress in patients with acute coronary syndrome. Biomed.Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2005; 149: 83-87
  Google Scholar
• 62. Sroka Z., Gamian A., Cisowski W.: Niskocząsteczkowe związkiprzeciwutleniające pochodzenia naturalnego. Postępy Hig. Med.Dośw., 2005; 59: 34-41
  Google Scholar
• 63. Vostálová J., Galandáková A., Svobodová A.R., Kajabová M.,Schneiderka P., Zapletalová J., Strebl P., Zadražil J.: Stabilization ofoxidative stress 1 year after kidney transplantation: effect of calcineurinimmunosuppressives. Ren. Fail., 2012; 34: 952-959
  Google Scholar
• 64. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., NguyenKhoaT., Nguyen A.T., Zingraff J., Jungers P., Descamps-Latscha B.:Advanced oxidation protein products as a novel marker of oxidativestress in uremia. Kidney Int., 1996; 49: 1304-1313
  Google Scholar
• 65. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., CapeillereBlandinC., Nguyen A.T., Canteloup S., Dayer J.M., Jungers P., DrüekeT., Descamps-Latscha B.: Advanced oxidation protein products asnovel mediators of inflammation and monocyte activation in chronicrenal failure. J. Immunol., 1998; 161: 2524-2532
  Google Scholar
• 66. Witko-Sarsat V., Gausson V., Descamps-Latscha B.: Are advancedoxidation protein products potential uremic toxins? Kidney Int.Suppl., 2003; 84: S11-S14
  Google Scholar
• 67. Witko-Sarsat V., Nguyen-Khoa T., Jungers P., Drüeke T.B., Descamps-LatschaB.: Advanced oxidation protein products as a novelmolecular basis of oxidative stress in uraemia. Nephrol. Dial. Transplant.,1999; 14 (Suppl. 1): 76-78
  Google Scholar
• 68. Yelken B., Caliskan Y., Gorgulu N., Altun I., Yilmaz A., Yazici H.,Oflaz H., Yildiz A.: Reduction of uric acid levels with allopurinoltreatment improves endothelial function in patients with chronickidney disease. Clin. Nephrol., 2012; 77: 275-282
  Google Scholar
• 69. Zadrazil J., Horak P., Strebl P., Krejci K., Kajabova M., SchneiderkaP., Zapletalova J., Galandakova A., Vostalova J., Vaverkova H.: Invivo oxidized low-density lipoprotein (ox-LDL) aopp and tas afterkidney transplantation: a prospective, randomized one year studycomparing cyclosporine A and tacrolimus based regiments. Biomed.Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2012; 156: 14-20
  Google Scholar
• 70. Zhou L.L., Cao W., Xie C., Tian J., Zhou Z., Zhou Q., Zhu P., Li A.,Liu Y., Miyata T., Hou F.F., Nie J.: The receptor of advanced glycationend products plays a central role in advanced oxidation proteinproducts-induced podocyte apoptosis. Kidney Int., 2012; 82: 759-770
  Google Scholar

Full text